Tennis champion Serena Williams has disclosed that a GLP-1 medication assisted her in losing 31 pounds (14 kilograms) following the birth of her second daughter, Adira, in 2023. In a conversation with Vogue, Williams noted that solely relying on diet and exercise was insufficient to achieve her weight objectives.
Now serving as a spokesperson for telehealth provider Ro, which provides GLP-1 medications such as Zepbound and Wegovy, Williams elaborated on how the medication helped her manage her appetite and sustain a feeling of fullness for extended periods. She emphasized that utilizing medical support for weight management is a legitimate option and should not be viewed negatively.
“At times, your body needs assistance beyond just diet and exercise,” Williams remarked. “Seeking help when necessary is a responsible action and should be normalized.”
GLP-1 medications, initially created for type 2 diabetes, have gained popularity for weight management due to their ability to slow digestion and help control hunger. However, health professionals caution that these medications can lead to side effects like nausea or digestive problems, and in rare cases, more severe complications. Reports from the UK in early 2025 indicated 85 deaths potentially associated with these treatments, underscoring the necessity of medical oversight.
Williams’ candidness about her experience has sparked renewed public dialogue regarding medical interventions for weight loss, especially after childbirth. Her honest narrative encourages others to seek professional advice when dealing with weight challenges, highlighting that asking for support is a strong and informed decision.
By sharing her story, Williams seeks to foster open discussions about health, wellness, and body image, while advocating for the safe and effective use of medical treatments in conjunction with lifestyle changes.